Golden Seeds company Concerto Biosciences announced that the U.S. FDA has cleared its Investigational New Drug application to initiate a Phase 1, first-in-human trial of Ensemble No.2 (ENS-002), an investigational live biotherapeutic product to treat atopic dermatitis. Read more here.